Business, energy, technology, markets and global industry news from Business News Today

Memorial Sloan Kettering Cancer Center

PharmaDeviceNews Memorial Sloan Kettering Cancer Center
Tempus AI’s PRISM2 pathology foundation model showed strong retrospective performance across cancer detection, biomarker prediction and survival analysis, strengthening interest in general-purpose artificial intelligence for digital pathology. Representative image.
Medical Devices & Diagnostics

Tempus AI trained PRISM2 on 2.3m pathology slides. Can one model detect cancer and predict what happens next?

Tempus AI’s PRISM2 foundation model matched or exceeded specialised pathology products across several retrospective cancer-detection tests while also supporting biomarker and survival predictions. The results strengthen the case for general-purpose pathology artificial intelligence, but PRISM2 is not yet an FDA-authorised diagnostic device.

Read More
One Biosciences’ FFPE single-cell tumour profiling research highlights how routine pathology samples could support deeper analysis of cancer cells, immune populations and the tumour microenvironment across multiple cancer types. Representative image.
Medical Devices & Diagnostics

Can One Biosciences bring single-cell transcriptomics into routine cancer pathology?

One Biosciences reports an FFPE single-cell workflow across six cancers, but clinical utility and prospective validation remain the next tests.

Read More
Representative image of an AI-enabled precision oncology research meeting, illustrating how SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center could turn cancer data into a precision medicine engine.
Medical Devices & Diagnostics

Can SOPHiA GENETICS and Memorial Sloan Kettering turn oncology data into a precision medicine engine?

SOPHiA GENETICS and Memorial Sloan Kettering aim to turn cancer data into precision oncology infrastructure. Can the hub deliver?

Read More
Pharma & Biotech

What Juniper Biosciences’ MSK collaboration means for radiation dose de-escalation strategies

Find out how Juniper Biosciences is using FMISO imaging to personalize radiation therapy and reduce toxicity in head and neck cancer.

Read More